ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
Hansa Medical AB, a biopharmaceutical company developing novel immunomodulatory enzymes, today announced that the board of directors have appointed Søren Tulstrup as new President and CEO of Hansa Medical effective today March 20, 2018.
SP Industries Inc. has announced the appointment of Brian Larkin as its President and Chief Executive Officer effective February 19th, replacing William (Bill) Downs who recently retired.
Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces the appointment of David Colpman as a non-executive director to its Board of Directors.
Company Co-founder Josef von Rickenbach to retire after 35 years of leadership; serve as Chairman of the Board.
SOTIO, a biotechnology company belonging to the PPF Group, announces today the appointment of Professor Radek píek as Chief Executive Officer.
Today Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect.
Rentschler Biopharma SE, a service provider for biopharmaceuticals, today announced the appointment of Mr. Federico Pollano as the new Senior Vice President of Business Development, effective March 1.
Paquet is a French national who since November 2015 has served as one of the three Deputy Secretaries-General of the Juncker Commission, and has now been been appointed as Director General of DG Research and Innovation
Mereo BioPharma Group plc, a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, today announced the appointment of Wills Hughes-Wilson as Head of Patient Access and Commercial Planning.